Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Jan 6, 2020--
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday January 13, 2020. The presentation will begin at 10:30 A.M. Pacific Time (1:30 P.M. Eastern Time), and a Q&A session will follow the presentation at 11:00 A.M. Pacific Time (2:00 P.M. Eastern Time).
To access live webcasts of the presentation and the Q&A sessions, visit Teva’s Investor Relations website at http://ir.tevapharm.com.
An archived versions of the presentation and Q&A sessions will be available approximately one hour after the end of the sessions at the same location.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2019 and in our Annual Report on Form 10-K for the year ended December 31, 2018, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200106005997/en/
CONTACT: IR Contacts
Kevin C. Mannix
972 (3) 9267516PR Contacts
972 (54) 888 5898
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MIDDLE EAST ISRAEL
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Teva Pharmaceutical Industries Ltd.
Copyright Business Wire 2020.
PUB: 01/06/2020 05:22 PM/DISC: 01/06/2020 05:22 PM